Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration

We aimed to identify whether drug-free remission could be achieved in patients with very early rheumatoid arthritis (RA) with poor prognosis factors by treatment with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirteen patients with very early RA, whose disease was considered to have...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2012-06, Vol.22 (3), p.346-352
Main Authors: Kita, Junko, Tamai, Mami, Arima, Kazuhiko, Nakashima, Yoshikazu, Suzuki, Takahisa, Kawashiri, Shin-ya, Iwamoto, Naoki, Okada, Akitomo, Koga, Tomohiro, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, Ida, Hiroaki, Aoyagi, Kiyoshi, Uetani, Masataka, Eguchi, Katsumi, Kawakami, Atsushi
Format: Article
Language:English
Subjects:
Aged
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - diagnostic imaging
Arthritis, Rheumatoid - drug therapy
Arthrography
Clinical outcomes
Disease Progression
Drug therapy
Female
Glucocorticoids - therapeutic use
Humans
Male
Medicine
Medicine & Public Health
Methotrexate - therapeutic use
Middle Aged
Original Article
Orthopedics
Remission Induction
Rheumatoid arthritis
Rheumatology
Severity of Illness Index
Treatment Outcome
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to identify whether drug-free remission could be achieved in patients with very early rheumatoid arthritis (RA) with poor prognosis factors by treatment with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirteen patients with very early RA, whose disease was considered to have highly erosive potential, were included. Magnetic resonance imaging (MRI)-proven bone edema and autoantibodies were determined in these patients. A treat-to-target strategy initiated with synthetic DMARDs was employed for 12 months. If the patients achieved simplified disease activity index (SDAI) remission along with a reduction of the RA MRI scoring bone edema score to
ISSN:1439-7595
1439-7609
DOI:10.1007/s10165-011-0522-8